[go: up one dir, main page]

WO2000076490A3 - Methodes de traitement de la frequence exageree des mictions ainsi que les mictions imperieuses a l'aide de oxybutynine-(s) optiquement pure et compositions a cet effet - Google Patents

Methodes de traitement de la frequence exageree des mictions ainsi que les mictions imperieuses a l'aide de oxybutynine-(s) optiquement pure et compositions a cet effet Download PDF

Info

Publication number
WO2000076490A3
WO2000076490A3 PCT/US2000/040183 US0040183W WO0076490A3 WO 2000076490 A3 WO2000076490 A3 WO 2000076490A3 US 0040183 W US0040183 W US 0040183W WO 0076490 A3 WO0076490 A3 WO 0076490A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxybutynin
urgency
treating urinary
compositions
urinary frequency
Prior art date
Application number
PCT/US2000/040183
Other languages
English (en)
Other versions
WO2000076490A2 (fr
Inventor
Paul D Rubin
Original Assignee
Sepracor Inc
Paul D Rubin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc, Paul D Rubin filed Critical Sepracor Inc
Priority to AU64036/00A priority Critical patent/AU6403600A/en
Publication of WO2000076490A2 publication Critical patent/WO2000076490A2/fr
Publication of WO2000076490A3 publication Critical patent/WO2000076490A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette méthode permet de traiter la fréquence exagérée des mictions ainsi que les mictions impérieuses tout en évitant le risque concomitant lié aux réactions indésirables associées à l'oxybutynine racémique. La méthode consiste à administrer une quantité efficace du point de vue thérapeutique d'oxybutynine-(S) ou un sel de celle-ci, admissible du point de vue thérapeutique, quasiment exempt de son énantiomère R. L'invention a également trait à des compositions à usage pharmaceutique renfermant de l'oxybutynine-(S) ou un sel de celle-ci, admissible du point de vue thérapeutique, quasiment exempt de son énantiomère R, à un antibiotique ainsi qu'à un excipient admissible du point de vue pharmaceutique.
PCT/US2000/040183 1999-06-10 2000-06-09 Methodes de traitement de la frequence exageree des mictions ainsi que les mictions imperieuses a l'aide de oxybutynine-(s) optiquement pure et compositions a cet effet WO2000076490A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64036/00A AU6403600A (en) 1999-06-10 2000-06-09 Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32969699A 1999-06-10 1999-06-10
US09/329,696 1999-06-10

Publications (2)

Publication Number Publication Date
WO2000076490A2 WO2000076490A2 (fr) 2000-12-21
WO2000076490A3 true WO2000076490A3 (fr) 2002-03-21

Family

ID=23286590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/040183 WO2000076490A2 (fr) 1999-06-10 2000-06-09 Methodes de traitement de la frequence exageree des mictions ainsi que les mictions imperieuses a l'aide de oxybutynine-(s) optiquement pure et compositions a cet effet

Country Status (2)

Country Link
AU (1) AU6403600A (fr)
WO (1) WO2000076490A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377956B2 (en) 2010-03-01 2013-02-19 Xenoport, Inc. Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273818A (ja) * 1991-02-28 1992-09-30 Kissei Pharmaceut Co Ltd 経皮投与製剤
JPH05339151A (ja) * 1992-05-30 1993-12-21 Kodama Kk 持効性塩酸オキシブチニン製剤
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
WO1996033678A1 (fr) * 1995-04-26 1996-10-31 Theratech, Inc. Utilisation de la triacetine comme stimulation de penetration transdermique
WO1996037202A1 (fr) * 1995-05-22 1996-11-28 Alza Corporation Forme galenique contenant de l'oxybutynine
WO1998000126A1 (fr) * 1996-06-28 1998-01-08 Sepracor, Inc. Utilisation de (s)-oxybutynine et de (s)-desethyloxybutynine pour traiter l'incontinence urinaire
WO1999024106A1 (fr) * 1997-11-06 1999-05-20 Situs Corporation Infuseur intravesical
WO1999048494A1 (fr) * 1998-03-26 1999-09-30 Alza Corporation Composition d'oxybutine a liberation continue et effet de xerostomie reduit

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273818A (ja) * 1991-02-28 1992-09-30 Kissei Pharmaceut Co Ltd 経皮投与製剤
JPH05339151A (ja) * 1992-05-30 1993-12-21 Kodama Kk 持効性塩酸オキシブチニン製剤
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
WO1996033678A1 (fr) * 1995-04-26 1996-10-31 Theratech, Inc. Utilisation de la triacetine comme stimulation de penetration transdermique
WO1996037202A1 (fr) * 1995-05-22 1996-11-28 Alza Corporation Forme galenique contenant de l'oxybutynine
WO1998000126A1 (fr) * 1996-06-28 1998-01-08 Sepracor, Inc. Utilisation de (s)-oxybutynine et de (s)-desethyloxybutynine pour traiter l'incontinence urinaire
WO1999024106A1 (fr) * 1997-11-06 1999-05-20 Situs Corporation Infuseur intravesical
WO1999048494A1 (fr) * 1998-03-26 1999-09-30 Alza Corporation Composition d'oxybutine a liberation continue et effet de xerostomie reduit

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199404, Derwent World Patents Index; AN 1994-031722, XP002183937 *
PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 *

Also Published As

Publication number Publication date
WO2000076490A2 (fr) 2000-12-21
AU6403600A (en) 2001-01-02

Similar Documents

Publication Publication Date Title
CA2211400A1 (fr) Traitement de l'incontinence urinaire par la (s)-oxybutynine et la (s)-desethyloxybutynine
CA2257121A1 (fr) Methodes et compositions pour le traitement de l'incontinence urinaire utilisant (s)-oxybutynine
AU4856097A (en) Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments
MY127946A (en) Therapeutic formulation for administering tolterodine with controlled release
AU3215597A (en) Method of inhibiting fibrosis with a somatostatin agonist
AU7031500A (en) Therapeutic quinazoline compounds
WO2000071108A3 (fr) Procedes de traitement de l'asthme a l'aide de s-oxybutynine
CA2180535A1 (fr) Procede de traitement du psoriasis par omeprazole ou autres composes apparentes
MY129130A (en) (+)-norcisapride
WO1999033450A3 (fr) Agents therapeutiques
WO2000051582A3 (fr) Procedes de traitement de l'apnee et de troubles de l'apnee a l'aide de r(+) ondansetron optiquement pur
DK0966285T3 (da) Anvendelse af (+)mefloquin til behandling af malaria
AU4976599A (en) Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
WO2000076490A3 (fr) Methodes de traitement de la frequence exageree des mictions ainsi que les mictions imperieuses a l'aide de oxybutynine-(s) optiquement pure et compositions a cet effet
WO2000010554A3 (fr) Procedes et compositions employant le vigabatrin s(+) optiquement pur
WO2003002059A3 (fr) Metabolites de tolterodine
AU4039799A (en) Method for the racemization of optically active amines
BG104416A (en) (1r, 2s,4r)-(-)-2-[(2'-{n,n-dimethylamino}-ethoxy)]-2- [phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane of high purity and its pharmaceutically acceptable with acid salts, method for the preparation of the compounds and medicaments containing one or more of them and their use
WO2001000187A3 (fr) Agents therapeutiques
AU4034699A (en) Method for racemization of optically active amines
AU1039492A (en) Process for the preparation of racemic and optically active 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and its precursors
WO1999033454A3 (fr) Procyclidine-s aux fins du traitement de l'incontinence urinaire
WO1996021670A3 (fr) Fusacandines antifongiques
AU2668201A (en) Method for the production of optically active cyanohydrins using r-oxynitrilase
WO1999033453A3 (fr) R-procyclidine utilisee dans le traitement de l'incontinence urinaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP